» Articles » PMID: 37704784

Mesenchymal Stromal Cells Confer Breast Cancer Doxorubicin Resistance by Producing Hyaluronan

Overview
Journal Oncogene
Date 2023 Sep 13
PMID 37704784
Authors
Affiliations
Soon will be listed here.
Abstract

Chemotherapy resistance represents a major cause of therapeutic failure and mortality in cancer patients. Mesenchymal stromal cells (MSCs), an integral component of tumor microenvironment, are known to promote drug resistance. However, the detailed mechanisms remain to be elucidated. Here, we found that MSCs confer breast cancer resistance to doxorubicin by diminishing its intratumoral accumulation. Hyaluronan (HA), a major extracellular matrix (ECM) product of MSCs, was found to mediate the chemoresistant effect. The chemoresistant effect of MSCs was abrogated when hyaluronic acid synthase 2 (HAS2) was depleted or inhibited. Exogenous HA also protected tumor grafts from doxorubicin. Molecular dynamics simulation analysis indicates that HA can bind with doxorubicin, mainly via hydrophobic and hydrogen bonds, and thus reduce its entry into breast cancer cells. This mechanism is distinct from the reported chemoresistant effect of HA via its receptor on cell surface. High HA serum levels were also found to be positively associated with chemoresistance in breast cancer patients. Our findings indicate that the HA-doxorubicin binding dynamics can confer cancer cells chemoresistance. Reducing HA may enhance chemotherapy efficacy.

Citing Articles

Hydrogel-based platforms for site-specific doxorubicin release in cancer therapy.

Zang C, Tian Y, Tang Y, Tang M, Yang D, Chen F J Transl Med. 2024; 22(1):879.

PMID: 39350207 PMC: 11440768. DOI: 10.1186/s12967-024-05490-3.


Deciphering Drug Resistance: Investigating the Emerging Role of Hyaluronan Metabolism and Signaling and Tumor Extracellular Matrix in Cancer Chemotherapy.

Vitale D, Parnigoni A, Viola M, Karousou E, Sevic I, Moretto P Int J Mol Sci. 2024; 25(14).

PMID: 39062846 PMC: 11276752. DOI: 10.3390/ijms25147607.


COL5A1 promotes triple-negative breast cancer progression by activating tumor cell-macrophage crosstalk.

Chen X, Ma C, Li Y, Liang Y, Chen T, Han D Oncogene. 2024; 43(23):1742-1756.

PMID: 38609499 DOI: 10.1038/s41388-024-03030-3.


Hyaluronic acid metabolism and chemotherapy resistance: recent advances and therapeutic potential.

Liu Z, Hou P, Fang J, Shao C, Shi Y, Melino G Mol Oncol. 2023; 18(9):2087-2106.

PMID: 37953485 PMC: 11467803. DOI: 10.1002/1878-0261.13551.

References
1.
Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

2.
Harbeck N, Gnant M . Breast cancer. Lancet. 2016; 389(10074):1134-1150. DOI: 10.1016/S0140-6736(16)31891-8. View

3.
Ostman A . The tumor microenvironment controls drug sensitivity. Nat Med. 2012; 18(9):1332-4. DOI: 10.1038/nm.2938. View

4.
Meads M, Gatenby R, Dalton W . Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer. 2009; 9(9):665-74. DOI: 10.1038/nrc2714. View

5.
Muerkoster S, Wegehenkel K, Arlt A, Witt M, Sipos B, Kruse M . Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta. Cancer Res. 2004; 64(4):1331-7. DOI: 10.1158/0008-5472.can-03-1860. View